Methods for treating fungal infections
Disclosed herein are methods of treating fungal infections in a patient, comprising identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein.
1. A method of therapeutically treating a patient having an echinocandin- or fluconazole-resistant fungal infection associated with Candida auris , the method comprising:
identifying a patient having an echinocandin- or fluconazole-resistant Candida auris infection;
administering a treatment composition to the patient, the treatment composition including one or more CSA compounds of Formula IV:
where,
R 3 , R 7 , and R 12 are unsubstituted aminoalkyloxy; and
R 18 is unsubstituted alkylaminoalkyl; and
the treatment composition killing or deactivating Candida auris to therapeutically treat the patient.
2. The method of claim 1 , wherein the treatment composition further comprises a carrier formulated as a wash or spray.
3. The method of claim 1 , wherein administering the treatment composition to the patient comprises applying the treatment composition to an open wound.
4. The method of claim 1 , wherein administering the treatment composition to the patient comprises applying the treatment composition to a wound associated with a surgical site.
5. The method of claim 4 , wherein administering the treatment composition to the patient comprises applying the treatment composition as a post-surgical spray.
6. The method of claim 1 , wherein administering the treatment composition to the patient comprises applying the treatment composition at or near a catheter insertion site.
7. The method of claim 1 , wherein the patient is immunocompromised.
8. The method of claim 1 , wherein the patient is not immunocompromised.
9. The method of claim 1 , wherein the fungal infection is additionally resistant to amphotericin B.
10. The method of claim 1 , wherein the fungal infection is a systemic infection.
11. The method of claim 1 , wherein administering the treatment composition to the patient comprises administering the treatment composition with at least one non-CSA therapeutic agent selected from the group consisting of an antifungal agent, an antibiotic, a non-steroidal anti-inflammatory agent, an anti-viral agent, an anti-retroviral agent, an anti-pyretic, an anti-emetic, an immunomodulator, a chemotherapeutic agent, an anti-histamine, an opioid receptor agonist, an anti-cholinergic, and a beta 2 -adrenoreceptor agonist.
12. The method of claim 1 , wherein administering the treatment composition to the patient comprises applying the treatment composition via any one or more of topical application, inhalation, intravenous injection, subcutaneous injection, intraperitoneal injection, depot injection, intramuscular injection, transdermal patch application, ear drops, or eye drops.
13. The method of claim 1 , wherein identifying the patient comprises identifying the patient under care within a healthcare facility.
14. The method of claim 1 , wherein administering the treatment composition to the patient comprises administering the treatment composition in conjunction with one or more separate antibiotics or antifungals to prevent post-antimicrobial-therapy emergence of a Candida auris infection.
15. A method of therapeutically treating an echinocandin- or fluconazole-resistant fungal infection associated with Candida auris , the method comprising:
identifying a patient having an echinocandin- or fluconazole-resistant fungal infection;
administering a treatment composition to an open wound or surgical site of the patient, the treatment composition being configured as a wash or spray and including one or more CSA compounds of Formula IV:
where,
R 3 , R 7 , and R 12 are unsubstituted aminoalkyloxy; and
R 18 is unsubstituted alkylaminoalkyl; and
the treatment composition killing or deactivating Candida auris to therapeutically treat the echinocandin- or fluconazole-resistant fungal infection at the open wound or surgical site.
16. The method of claim 15 , wherein administering the treatment composition comprises applying the treatment composition at or near a catheter insertion site.
17. A method of therapeutically treating a echinocandin- or fluconazole-resistant fungal infection associated with Candida auris , the method comprising:
applying a treatment composition to a medical device prior to use of the medical device on a patient, the treatment composition including one or more CSA compounds of Formula IV:
where,
R 3 , R 7 , and R 12 are unsubstituted aminoalkyloxy; and
R 18 is unsubstituted alkylaminoalkyl; and
the treatment composition killing or deactivating Candida auris to therapeutically treat the echinocandin- or fluconazole-resistant fungal infection.
18. The method of claim 17 , wherein applying a treatment composition to the medical device comprises applying the treatment composition to a catheter.
19. The method of claim 1 , wherein the CSA compound is selected from the group consisting of CSA-13, CSA-92, CSA-131, and CSA-138.
20. The method of claim 1 , wherein the CSA compound comprises CSA-131.